Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy ; day:21 ; month:3 ; year:2024 ; pages:1-8
Neurological sciences ; (21.3.2024), 1-8

Creator: Pensato, Umberto
Pondrelli, Federica
Philippis, Chiara de
Asioli, Gian Maria
Crespi, Alessandra
Buizza, Alessandro
Mannina, Daniele
Casadei, Beatrice
Maffini, Enrico
Straffi, Laura
Marcheselli, Simona
Zinzani, Pier Luigi
Bonifazi, Francesca
Guarino, Maria
Bramanti, Stefania

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10072-024-07481-0

URN: urn:nbn:de:101:1-2406182103004.011892337378

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Pensato, Umberto
Pondrelli, Federica
Philippis, Chiara de
Asioli, Gian Maria
Crespi, Alessandra
Buizza, Alessandro
Mannina, Daniele
Casadei, Beatrice
Maffini, Enrico
Straffi, Laura
Marcheselli, Simona
Zinzani, Pier Luigi
Bonifazi, Francesca
Guarino, Maria
Bramanti, Stefania
SpringerLink (Online service)

Other Objects (12)

Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Psychiatric implications of anti-seizure medications in epileptic population

Seizure prophylaxis in the neuroscience intensive care unit

Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo

Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy

Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells

Hochschulschrift

Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie

Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning

Seizure Management and Prophylaxis Considerations in Patients with Brain Tumors

Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Psychiatric implications of anti-seizure medications in epileptic population

Seizure prophylaxis in the neuroscience intensive care unit

Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo

Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy

Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells

Hochschulschrift

Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie

Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning

Seizure Management and Prophylaxis Considerations in Patients with Brain Tumors

Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Psychiatric implications of anti-seizure medications in epileptic population

Seizure prophylaxis in the neuroscience intensive care unit

Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo

Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy

Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells

Hochschulschrift

Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie

Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning

Seizure Management and Prophylaxis Considerations in Patients with Brain Tumors

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Psychiatric implications of anti-seizure medications in epileptic population

Seizure prophylaxis in the neuroscience intensive care unit

Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo

Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy

Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells

Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie

Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning

Seizure Management and Prophylaxis Considerations in Patients with Brain Tumors

Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Psychiatric implications of anti-seizure medications in epileptic population

Seizure prophylaxis in the neuroscience intensive care unit

Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo

Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy

Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells

Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie

Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning

Seizure Management and Prophylaxis Considerations in Patients with Brain Tumors

Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Psychiatric implications of anti-seizure medications in epileptic population

Seizure prophylaxis in the neuroscience intensive care unit

Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo

Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy

Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells

Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie

Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning

Seizure Management and Prophylaxis Considerations in Patients with Brain Tumors

Related objects

Reset password